Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative Study on the Efficacy and Safety of Initial Combination Therapy of Low Dose Propiverine Hydrocholoride Compared to Alpha-antagonist Monotherapy in men with BPH with Overactive bladder : A Prospective Placebo Controlled Study.

Next Previous
Trial Profile

Comparative Study on the Efficacy and Safety of Initial Combination Therapy of Low Dose Propiverine Hydrocholoride Compared to Alpha-antagonist Monotherapy in men with BPH with Overactive bladder : A Prospective Placebo Controlled Study.

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Sep 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Propiverine (Primary) ; Alfuzosin
  • Indications Benign prostatic hyperplasia; Overactive bladder
  • Focus Therapeutic Use
  • Acronyms SYNERGY

    • Most Recent Events

    • 13 Feb 2013 Planned End Date changed from 1 May 2013 to 29 Sep 2013 as reported by Korean Clinical Trials Register.
    • 09 May 2012 Planned end date 1 May 2013 added as reported by Korean Clinical Trials Register record.
    • 09 May 2012 Status changed from not yet recruiting to recruiting as reported by Korean Clinical Trials Register record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top